Table 2.

Summary of the effects of Siglec engagement in vitro on eosinophils, mast cells, and basophils.

Cell Type	Siglec Targeted	Effect
Eosinophil	Siglec-7	Inhibition of GM-CSF-induced degranulation and cytokine secretion (Legrand et al., 2019b)
	Siglec-8	Cell death (upon extensive crosslinking or antibody ligation after cytokine priming) (Na et al., 2012; Nutku et al., 2003; Nutku-Bilir et al., 2008)
	Siglec-F (mouse eosinophils)	Slight induction of ROS- and SFK-independent cell death (Mao et al., 2013); enhancement of IL-33-induced cellular activation and cytokine/chemokine secretion (Westermann et al., 2022)
Mast cell	Siglec-3	Inhibition of LAD2 cell degranulation, inhibition of IgE-mediated bronchoconstriction in vitro (with FcεRI co-crosslinking) (Duan et al., 2019)
	Siglec-6	Inhibition of degranulation and cytokine/chemokine secretion (enhanced by co-crosslinking with FcεRI) (Robida et al., 2022; Yu et al., 2018)
	Siglec-7	Inhibition of degranulation and cytokine/chemokine secretion (upon co-crosslinking with FcεRI) (Mizrahi et al., 2014)
	Siglec-8	Inhibition of calcium flux, degranulation, and cytokine/chemokine secretion (upon antibody ligation or co-crosslinking with FcεRI); inhibition of IL-33-mediated cytokine/chemokine secretion (Korver et al., 2022; Yokoi et al., 2008)
Basophil	Siglec-7	Inhibition of degranulation (Mizrahi et al., 2014)